Getein Biotech(603387)

Search documents
基蛋生物: 基蛋生物:董事会战略委员会实施细则(2025年8月)
Zheng Quan Zhi Xing· 2025-08-29 14:19
General Principles - The implementation rules for the Strategic Committee of the company are established to enhance core competitiveness, determine development planning, and improve decision-making processes [1][2] - The Strategic Committee is a specialized working body set up by the Board of Directors, responsible for researching and proposing suggestions on the company's long-term development strategy and major investment decisions [1][2] Composition of the Committee - The Strategic Committee consists of three members, including at least one independent director [3] - The chairman of the committee is the chairman of the board, who is responsible for presiding over the committee's work [3][4] Responsibilities and Authority - The main responsibilities of the Strategic Committee include researching and proposing suggestions on long-term development strategies, major investment financing plans, significant capital operations, and other major matters affecting the company's development [8] - The committee is responsible to the Board of Directors, and its proposals are submitted for board review and decision [8] Decision-Making Procedures - A working group is responsible for preparing the committee's decisions, providing relevant materials, and conducting preliminary reviews [10] - The committee holds meetings to discuss proposals from the working group and submits the results to the Board of Directors [11] Meeting Rules - The Strategic Committee must hold at least two meetings per year, with notifications sent two days in advance [12] - A meeting requires the presence of at least two-thirds of the members to be valid, and decisions must be approved by a majority [13][14] Confidentiality and Record-Keeping - Members attending meetings have confidentiality obligations and must not disclose information without authorization [21] - Meeting records must be kept, and attendees are required to sign the records [19]
基蛋生物: 基蛋生物:审计委员会议事规则(2025年8月)
Zheng Quan Zhi Xing· 2025-08-29 14:19
Core Points - The audit committee of the company is established to enhance the decision-making function of the board and ensure effective supervision of the management [1][2] - The audit committee consists of three members, including two independent directors, with a professional accountant serving as the chairperson [2][3] - The main responsibilities of the audit committee include supervising external and internal audits, reviewing financial reports, and assessing the effectiveness of internal controls [3][5] Group 1 - The audit committee is responsible for evaluating external audit work and proposing the hiring or replacement of external audit firms [3][10] - The committee must approve financial disclosures and significant accounting changes before submission to the board [5][6] - The committee has the authority to investigate unusual business conditions and can hire external professionals for assistance if necessary [3][12] Group 2 - The audit committee meetings must be convened with at least two-thirds of the members present to make decisions [10][11] - The committee is required to maintain confidentiality regarding the matters discussed in meetings [14] - The rules governing the audit committee's operations are subject to national laws and regulations, and any conflicts will be resolved in favor of the latter [14][36]
基蛋生物: 基蛋生物:市值管理制度(2025年8月)
Zheng Quan Zhi Xing· 2025-08-29 14:19
基蛋生物科技股份有限公司 市值管理制度 基蛋生物科技股份有限公司 市值管理制度 第一章 总则 第一条 为加强基蛋生物科技股份有限公司(以下简称"公司")市值管理, 切实推动公司投资价值提升,增强投资者回报,维护投资者利益,根据《中华人 民共和国公司法》《中华人民共和国证券法》《上市公司信息披露管理办法》《上 市公司监管指引第 10 号——市值管理》等法律法规、规范性文件和《公司章程》 等规定,制定本制度。 第二条 本制度所称市值管理,是指公司以提高公司质量为基础,为提升投 资者回报能力和水平而实施的战略管理行为。 第三条 市值管理的基本原则包括: (一)合规性原则:公司应当在严格遵守相关法律法规、规范性文件、自律 监管规则以及《公司章程》等内部规章制度的前提下开展市值管理工作。 (三)科学性原则:公司的市值管理有其规律,应当依其规律进行科学管理, 科学研判影响公司投资价值的关键性因素,以提升公司质量为基础开展市值管理 工作。 (四)常态性原则:公司的市值成长是一个持续的和动态的过程,公司将及 时关注资本市场及公司股价动态,常态化主动跟进开展市值管理工作。 (五)诚实守信原则:公司在市值管理活动中应当注重诚信、 ...
基蛋生物: 基蛋生物:董事会提名、薪酬与考核委员会实施细则(2025年8月)
Zheng Quan Zhi Xing· 2025-08-29 14:19
Core Points - The implementation rules for the Nomination, Compensation, and Assessment Committee of the company aim to improve the governance structure and establish a sound system for the nomination, assessment, and compensation management of directors and senior management [1][2] - The committee is composed of independent and external directors, with independent directors holding a majority [2][3] - The committee's main responsibilities include researching selection criteria for directors and senior management, reviewing candidates, and proposing compensation policies [8][9][10] Group 1 - The committee is a specialized working body established by the board of directors and is accountable to the board [1] - The committee's term aligns with that of the board, and members can be re-elected [2] - The human resources department provides professional support and feedback on the implementation of the committee's decisions [2][3] Group 2 - The committee is responsible for proposing standards and procedures for selecting directors and senior management, as well as reviewing and recommending candidates [8][9] - The compensation and assessment committee specifically handles the formulation of assessment standards and compensation policies for directors and senior management [10][11] - The committee's proposals for director compensation must be approved by the board and submitted for shareholder review [11] Group 3 - The selection process for directors and senior management involves extensive communication and research on the company's needs [12] - The committee must conduct a thorough review of candidates' qualifications and obtain their consent before nomination [12][13] - The human resources department provides essential materials for the committee's reference, including financial and performance indicators [13][14] Group 4 - The evaluation process for directors and senior management includes self-assessment and performance evaluation based on established standards [15] - The committee meetings require a two-thirds attendance to be valid, and decisions should reflect independent opinions [15][16] - Meeting records must be kept, and confidentiality is required from all attendees [16][17]
基蛋生物: 基蛋生物:会计师事务所选聘制度(2025年8月)
Zheng Quan Zhi Xing· 2025-08-29 14:19
Core Viewpoint - The document outlines the selection and appointment procedures for accounting firms by the company, emphasizing the importance of maintaining shareholder interests and ensuring the quality and authenticity of financial information [1][2]. Group 1: General Principles - The company establishes a system for the selection of accounting firms to ensure compliance with relevant laws and regulations [1]. - The selection process must be approved by the audit committee, the board of directors, and ultimately the shareholders [1][2]. - Major shareholders and actual controllers are prohibited from interfering in the selection process before board and shareholder meetings [1] Group 2: Quality Requirements for Accounting Firms - Selected accounting firms must possess independent legal status and necessary qualifications as per regulatory requirements [2]. - Firms must have a solid organizational structure, internal management systems, and a good reputation without any significant regulatory penalties in the last three years [2][3]. - The evaluation of firms will consider their audit quality, professional ethics, and compliance with relevant laws [2][3]. Group 3: Selection Procedures - The audit committee is responsible for proposing the selection of accounting firms and overseeing the process [3][4]. - The selection can be conducted through competitive negotiations, public bidding, or other transparent methods [4]. - The evaluation criteria for firms will include audit fees, qualifications, past performance, and resource allocation [4][5]. Group 4: Appointment and Reappointment - The appointment of accounting firms is formalized through a business agreement after approval from the shareholders [6][7]. - The audit committee must evaluate the performance of the accounting firm annually before reappointment [7][8]. - Adjustments to audit fees can be made based on various economic factors, with specific disclosure requirements if fees decrease significantly [7][8]. Group 5: Termination and Replacement Procedures - The company must replace accounting firms under certain conditions, such as significant quality issues or failure to meet deadlines [9][10]. - The audit committee must conduct thorough investigations before recommending a replacement [9][10]. - Detailed disclosures regarding the reasons for termination and the performance of the previous firm are required [10][11]. Group 6: Supervision and Penalties - The audit committee is tasked with supervising the audit work and ensuring compliance with laws and internal policies [11][12]. - Violations by accounting firms can lead to penalties, including potential dismissal and financial liability for responsible individuals [11][12]. - The company must ensure that any significant issues with the audit firm are addressed promptly and transparently [12].
基蛋生物: 基蛋生物:对外担保管理制度(2025年8月)
Zheng Quan Zhi Xing· 2025-08-29 14:19
Core Viewpoint - The external guarantee management system of the company aims to strengthen internal controls, standardize guarantee behavior, and prevent guarantee risks in accordance with relevant laws and regulations [2][3]. Group 1: General Principles - The company defines "guarantee" as providing assurance, mortgage, pledge, lien, and deposit for others [2]. - The company must adhere to principles of equality, voluntariness, fairness, integrity, and mutual benefit when providing guarantees [2]. - The internal control system for guarantees should focus on risk control in key areas to ensure compliance with laws and regulations [2][3]. Group 2: Applicability and Decision-Making - The guarantee management system applies to the company and its wholly-owned and controlling subsidiaries [3]. - The shareholders' meeting and board of directors are the decision-making bodies for external guarantees, requiring approval before any guarantee contracts are signed [3][6]. - Guarantees provided to controlling subsidiaries do not require counter-guarantees, while guarantees to other parties must include counter-guarantees from capable entities [6][7]. Group 3: Guarantee Procedures - The company can provide guarantees to entities with independent legal status that meet specific conditions, including those with strong debt repayment capabilities [8][9]. - The board of directors must analyze the credit status and risks associated with the guarantee before approval [9][10]. - The company’s finance department is responsible for handling guarantee business and must ensure personnel are qualified and aware of risk management [7][10]. Group 4: Review and Approval - The board of directors must review the financial status and creditworthiness of the guaranteed party, rejecting guarantees if certain negative conditions are present [17][18]. - For guarantees exceeding 10% of the company's latest audited net assets, board approval is required, followed by shareholders' meeting approval [21][22]. - External professional institutions may be engaged to assess risks associated with guarantees when necessary [22]. Group 5: Contract Management and Disclosure - After approval, guarantee contracts must be signed by authorized representatives and should clearly define the scope, purpose, and duration of the guarantee [23][24]. - The company must manage guarantee contracts and related documents properly, ensuring their accuracy and completeness [26][27]. - If a guaranteed party fails to fulfill obligations, the company must take necessary remedial actions and report to the board [31][32]. Group 6: Responsibilities and Accountability - Company directors and management are held accountable for unauthorized guarantee contracts that cause damage to the company [37][38]. - Individuals responsible for guarantee approvals may face penalties for negligence or misconduct leading to financial losses [38][39].
基蛋生物(603387) - 基蛋生物:关于召开2025年第一次临时股东大会的通知
2025-08-29 14:17
证券代码:603387 证券简称:基蛋生物 公告编号:2025-036 基蛋生物科技股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 股东大会召开日期:2025年9月15日 本次股东大会采用的网络投票系统:上海证券交易所股东大会网络投票 系统 一、召开会议的基本情况 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人:董事会 (三)投票方式:本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间:2025 年 9 月 15 日 14 点 00 分 召开地点:南京市六合区沿江工业开发区博富路 9 号基蛋生物科技股份有限 公司四楼会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统:上海证券交易所股东大会网络投票系统 网络投票起止时间:自2025 年 9 月 15 日 至2025 年 9 月 15 日 采用上海证券交易所网络投票系统,通过交易系统投票平台的投票时 ...
基蛋生物(603387) - 基蛋生物:第四届监事会第七次会议决议公告
2025-08-29 14:16
证券代码:603387 证券简称:基蛋生物 公告编号:2025-030 基蛋生物科技股份有限公司 第四届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 基蛋生物科技股份有限公司(以下简称"公司")第四届监事会第七次会议的通知 已于2025年8月18日以电子邮件的方式发出,通知了全体监事和其他列席人员。公司本 次监事会会议于2025年8月29日以现场及通讯表决方式召开。会议应出席监事3人,实际 出席监事3人。会议由监事会主席李靖召集和主持,公司董事会秘书和财务负责人列席 了本次监事会会议。本次会议的召开符合《中华人民共和国公司法》和《基蛋生物科技 股份有限公司章程》及有关法律法规的规定,会议决议合法有效。 二、监事会会议审议情况 (一)审议并通过《关于公司〈2025年半年度报告〉及其摘要的议案》 公司根据2025年半年度的实际经营情况和财务状况,依照有关规定编制《2025年半 年度报告》及其摘要。 监事会认为:公司《2025年半年度报告》及其摘要的编制和审议程序符合法律、法 ...
基蛋生物(603387) - 基蛋生物:第四届董事会第七次会议决议公告
2025-08-29 14:15
基蛋生物科技股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 基蛋生物科技股份有限公司(以下简称"公司")第四届董事会第七次会议的通知 已于 2025 年 8 月 18 日以电子邮件形式向全体董事发出。本次会议于 2025 年 8 月 29 日 以现场及通讯表决方式召开。会议应出席董事 9 人,实际出席董事 9 人。本次会议由董 事长苏恩本先生主持,公司全体监事和高级管理人员列席了本次会议。本次会议的召开 符合《中华人民共和国公司法》和《基蛋生物科技股份有限公司章程》及有关法律法规 的规定,会议决议合法有效。 二、董事会会议审议情况 (一)审议并通过《关于公司〈2025 年半年度报告〉及其摘要的议案》 证券代码:603387 证券简称:基蛋生物 公告编号:2025-029 公司根据 2025 年半年度的实际经营情况和财务状况,依照有关规定编制《2025 年 半年度报告》及其摘要。董事会审核后认为公司编制的 2025 年半年度报告及其摘要, 可以全面、客观、 ...
基蛋生物(603387) - 基蛋生物:关于2025年半年度利润分配方案的公告
2025-08-29 14:15
关于2025年半年度利润分配方案的公告 证券代码:603387 证券简称:基蛋生物 公告编号:2025-031 每股分配比例:向全体股东每10股派发人民币0.9元(含税)。 基蛋生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 本次利润分配以实施权益分派股权登记日总股本数为基数,具体日期将 在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发生变 动的,拟维持分配总额不变,相应调整每股分配比例,并将另行公告具体调整情 况。 一、利润分配方案内容 截至 2025 年 6 月 30 日,公司合并报表归属于上市公司股东的净利润为人民 币 108,808,763.23 元 , 母 公 司 报 表 中 期 末 未 分 配 利 润 为 人 民 币 1,381,522,465.85 元(数据未经审计)。经第四届董事会第七次会议决议,公司 2025 年半年度拟以实施权益分派股权登记日登记的总股本为基数,向全体股东 每 10 股派发人民币 0.9 元(含税),以第四届董事会第七次会议召开日的 ...